Sindromi MIELOPROLIFERATIVE CRONICHE target: POLICITEMIA VERA
Contatti: Giulia Benevolo gbenevolo@cittadellasalute.to.it
AOU Città della Salute e della Scienza di Torino, SC Ematologia Universitaria – P.O. Molinette
Sindromi MIELOPROLIFERATIVE CRONICHE target: MIELOFIBROSI
Contatti: Giulia Benevolo gbenevolo@cittadellasalute.to.it
AOU Città della Salute e della Scienza di Torino, SC Ematologia Universitaria – P.O. Molinette
- A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor.
- A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis (BBI-TP-3654-102)
- A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL) (PAC-303)
- A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (KRT-232-115)
Contatti: PI Dott.ssa Eloise Beggiato ebeggiato@cittadellasalute.to.it 0116334418 Sub-I Dott. Giuseppe Lanzarone glanzarone@cittadellasalute.to.itS.C. Ematologia U – PO Molinette
- XPORT-MF-034 a phase 1/3 study to evaluate the efficacy and safety of selinexor, a selective inhibitor of nuclear export, in combination with ruxolitinib in treatment-naïve patients with myelofibrosis
- XPORT-MF-044 a phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with jak inhibitor-naïve myelofibrosis and moderate thrombocytopenia
Contatti: Valentina Giai vgiai@cittadellasalute.to.it 0116335551
Sindromi MIELOPROLIFERATIVE CRONICHE target: LEUCEMIA MIELOIDE CRONICA
Contatti: Marco Cerrano mcerrano@cittadellasalute.to.it 0116335551
- CAMN107AIT15 -DANTE:A phase II, single-arm, multicenter study of full treatment-free remission in patient with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have archived a sustained deep molecular response for at leats 1 year
Contatti: Valentina Giai vgiai@cittadellasalute.to.it 0116335551
- ITALY-TFR: Studio osservazionale in pazienti adulti con leucemia mieloide cronica (LMC) che hanno discontinuato inibitori di tirosin-kinasi (TKI) in Italia
- REGISTRO LMC: Studio osservazionale multicentrico retrospettivo e prospettico su pazienti affetti da leucemia mieloide cronica: raccolta di dati epidemiologici e clinici nella pratica clinica reale